Thalia Therapeutics Plc

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. Thalia Therapeutics Plc was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.